Gerresheimer, supplier to global pharma and healthcare industries, has acquired the Swiss company, Sensile Medical, extending its business model and enabling the company to offer drug delivery platforms with digital and electronic capabilities.
Acquisition
“We are accelerating our growth and laying vital groundwork for the years ahead,” said Rainer Beaujean, speaker of the management board and chief financial officer. “For Gerresheimer, Sensile Medical is a perfect fit, as it develops innovative products and platforms for drug delivery, including digital connectivity.
“Sensile Medical is already working with customers on highly successful projects dealing with devices for diabetics and patients with heart complaints and therapy areas such as Parkinson’s disease. Sensile Medical lays the foundation for a major extension of our business model in innovative application areas.”
Independently of this acquisition, Gerresheimer has also secured two major contracts — one for the manufacture of inhalers and the other for prefillable syringes for a major heparin producer.
“We have also secured two major orders in our normal business, meaning that we can expect higher revenue growth and increased profitability in the medium term,” added Beaujean. “The first half of the current financial year is going as expected, with earnings per share, in particular, performing well. We anticipate a strong second half year and have accordingly narrowed our revenue forecast to the upper end of the range.”